FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379142988> ?p ?o ?g. }

• W4379142988 endingPage "A015" @default.
• W4379142988 startingPage "A015" @default.
• W4379142988 abstract "Abstract Introduction Prostate cancer (CaP) will cause the deaths of more than 34,000 American men in 2022 because systemic treatments for metastatic CaP eventually fail. There is a need for actionable targets for novel treatments that work via entirely different mechanisms, bypass resistance to current therapies, and control the cellular processes that drive CaP progression to improve patient survival. We examine the contribution of citron kinase (CIT), a key mediator of cytokinesis, to CaP progression and explore the manner by which CIT impacts CaP cell behavior. Experimental procedures Cell proliferation and gene silencing, overexpression and mutation assays were performed in cell line models or PDX-derived organoids (PDXOs) reflecting treatment-resistant progression. Xenografting and tumorigenesis assays using cell lines that allow for CIT induction or repression were done in immunodeficient mice. Clinical relevance and translational potential of CIT was determined using immunohistochemistry and RNA-Seq assays combined with GSEA, MSigDB, rMATS and PCTA computational analyses. Mass spectrometry assays coupled with phospho-enrichment were done to identify CIT substrates; their interactions with CIT and RNA were confirmed via coIP and RNA-IP. Results We found that CIT controls CaP cell cycle progression and cell division and is overexpressed during clinical CaP progression. CIT overexpression was tumorigenic and overcame strategies to inhibit CaP growth. Conversely, CIT silencing inhibited the growth of cell lines and xenografts representing different stages of CaP progression and treatment resistance. Such silencing did not affect proliferation of benign epithelial prostate cells, indicating that CIT action is CaP-specific. CIT’s effects on CaP relied entirely on its kinase activity, which we isolated as druggable. Overexpression of kinase-dead CIT blunted CaP cell proliferation and pharmacological CIT inhibition decreased proliferation of treatment-resistant CaP cells and PDXOs, suggesting that CIT substrates mediate CaP growth. Using state-of-the-art proteomics approaches, we isolated the first CIT kinase substrates and found that over one-third function in RNA binding, metabolism and/or alternative splicing, a hallmark of CaP aggressiveness that is tightly controlled by phosphorylation. Combining RNA-Seq with bioinformatics analyses, we found that CIT induced alternative splicing patterns that were enriched in treatment-resistant castration-resistant CaP and neuroendocrine CaP. Moreover, putative CIT substrates were recruited to CIT-induced splicing sites, and CIT-controlled alternatively spliced transcripts differentially impacted CaP cell proliferation. Conclusion Collectively, these findings isolate CIT, and its kinase action, as a pivotal novel regulator of CaP progression. Moreover, CIT’s CaP driver function was mediated at least in part by clinically relevant alternative splicing events. These results suggest that blocking CIT or its dependent splicing events may overcome CaP-specific treatment resistance and progression. Citation Format: Chitra Rawat, Nidhi Singh, Gaurav Chauhan, Anja Rabljenovic, Salma Ben-Salem, Vishwa Vaghela, Varadha B. Venkadakrishnan, Jonathan MacDonald, Ujjwal Dahiya, Adam D. DePriest, Sanghee Lee, Michelle Muldong, Hyun-Tae Kim, Sangeeta Kumari, Qiang Hu, Eduardo Cortes, Scott M. Dehm, Amina Zoubeidi, Christina A.M. Jamieson, Marlo Nicolas, Jesse McKenney, Belinda Willard, Eric A. Klein, Cristina Magi-Galluzzi, Shaun R. Stauffer, Song Liu, Hannelore V. Heemers. Citron kinase is a novel driver of prostate cancer progression and controls alternative splicing associated with treatment-resistance [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr A015." @default.
• W4379142988 created "2023-06-03" @default.
• W4379142988 creator A5001069772 @default.
• W4379142988 creator A5011882158 @default.
• W4379142988 creator A5013491797 @default.
• W4379142988 creator A5014295844 @default.
• W4379142988 creator A5016927193 @default.
• W4379142988 creator A5017479094 @default.
• W4379142988 creator A5025300372 @default.
• W4379142988 creator A5026531632 @default.
• W4379142988 creator A5032641888 @default.
• W4379142988 creator A5034716746 @default.
• W4379142988 creator A5037739540 @default.
• W4379142988 creator A5042386055 @default.
• W4379142988 creator A5045961101 @default.
• W4379142988 creator A5049749003 @default.
• W4379142988 creator A5051446263 @default.
• W4379142988 creator A5055217733 @default.
• W4379142988 creator A5056585446 @default.
• W4379142988 creator A5062119044 @default.
• W4379142988 creator A5067662275 @default.
• W4379142988 creator A5069985314 @default.
• W4379142988 creator A5070499588 @default.
• W4379142988 creator A5077055515 @default.
• W4379142988 creator A5079152763 @default.
• W4379142988 creator A5081197036 @default.
• W4379142988 creator A5081653545 @default.
• W4379142988 creator A5084405217 @default.
• W4379142988 creator A5092073888 @default.
• W4379142988 date "2023-06-02" @default.
• W4379142988 modified "2023-10-14" @default.
• W4379142988 title "Abstract A015: Citron kinase is a novel driver of prostate cancer progression and controls alternative splicing associated with treatment-resistance" @default.
• W4379142988 doi "https://doi.org/10.1158/1538-7445.prca2023-a015" @default.
• W4379142988 hasPublicationYear "2023" @default.
• W4379142988 type Work @default.
• W4379142988 citedByCount "0" @default.
• W4379142988 crossrefType "journal-article" @default.
• W4379142988 hasAuthorship W4379142988A5001069772 @default.
• W4379142988 hasAuthorship W4379142988A5011882158 @default.
• W4379142988 hasAuthorship W4379142988A5013491797 @default.
• W4379142988 hasAuthorship W4379142988A5014295844 @default.
• W4379142988 hasAuthorship W4379142988A5016927193 @default.
• W4379142988 hasAuthorship W4379142988A5017479094 @default.
• W4379142988 hasAuthorship W4379142988A5025300372 @default.
• W4379142988 hasAuthorship W4379142988A5026531632 @default.
• W4379142988 hasAuthorship W4379142988A5032641888 @default.
• W4379142988 hasAuthorship W4379142988A5034716746 @default.
• W4379142988 hasAuthorship W4379142988A5037739540 @default.
• W4379142988 hasAuthorship W4379142988A5042386055 @default.
• W4379142988 hasAuthorship W4379142988A5045961101 @default.
• W4379142988 hasAuthorship W4379142988A5049749003 @default.
• W4379142988 hasAuthorship W4379142988A5051446263 @default.
• W4379142988 hasAuthorship W4379142988A5055217733 @default.
• W4379142988 hasAuthorship W4379142988A5056585446 @default.
• W4379142988 hasAuthorship W4379142988A5062119044 @default.
• W4379142988 hasAuthorship W4379142988A5067662275 @default.
• W4379142988 hasAuthorship W4379142988A5069985314 @default.
• W4379142988 hasAuthorship W4379142988A5070499588 @default.
• W4379142988 hasAuthorship W4379142988A5077055515 @default.
• W4379142988 hasAuthorship W4379142988A5079152763 @default.
• W4379142988 hasAuthorship W4379142988A5081197036 @default.
• W4379142988 hasAuthorship W4379142988A5081653545 @default.
• W4379142988 hasAuthorship W4379142988A5084405217 @default.
• W4379142988 hasAuthorship W4379142988A5092073888 @default.
• W4379142988 hasConcept C104317684 @default.
• W4379142988 hasConcept C119056186 @default.
• W4379142988 hasConcept C121608353 @default.
• W4379142988 hasConcept C173396325 @default.
• W4379142988 hasConcept C2779256057 @default.
• W4379142988 hasConcept C2780192828 @default.
• W4379142988 hasConcept C502942594 @default.
• W4379142988 hasConcept C54355233 @default.
• W4379142988 hasConcept C555283112 @default.
• W4379142988 hasConcept C62112901 @default.
• W4379142988 hasConcept C81885089 @default.
• W4379142988 hasConcept C86803240 @default.
• W4379142988 hasConceptScore W4379142988C104317684 @default.
• W4379142988 hasConceptScore W4379142988C119056186 @default.
• W4379142988 hasConceptScore W4379142988C121608353 @default.
• W4379142988 hasConceptScore W4379142988C173396325 @default.
• W4379142988 hasConceptScore W4379142988C2779256057 @default.
• W4379142988 hasConceptScore W4379142988C2780192828 @default.
• W4379142988 hasConceptScore W4379142988C502942594 @default.
• W4379142988 hasConceptScore W4379142988C54355233 @default.
• W4379142988 hasConceptScore W4379142988C555283112 @default.
• W4379142988 hasConceptScore W4379142988C62112901 @default.
• W4379142988 hasConceptScore W4379142988C81885089 @default.
• W4379142988 hasConceptScore W4379142988C86803240 @default.
• W4379142988 hasIssue "11_Supplement" @default.
• W4379142988 hasLocation W43791429881 @default.
• W4379142988 hasOpenAccess W4379142988 @default.
• W4379142988 hasPrimaryLocation W43791429881 @default.
• W4379142988 hasRelatedWork W2404653437 @default.
• W4379142988 hasRelatedWork W2531142332 @default.
• W4379142988 hasRelatedWork W2775401927 @default.
• W4379142988 hasRelatedWork W2898075173 @default.
• W4379142988 hasRelatedWork W2903968497 @default.
• W4379142988 hasRelatedWork W2964133775 @default.

• next